Blood test provides 'snapshot' of tumor drug response

(Medical Xpress) -- Counting the number of tumour cells in blood samples taken before and after treatment for advanced neuroendocrine tumors could provide a ‘snapshot’ of how well patients are responding within weeks of starting treatment, according to results from a study being presented at the American Society for Clinical Oncology cancer conference today (Monday).

The study, coordinated by researchers from the Research UK and NIHR Experimental Cancer Medicine Centre (ECMC) at UCL Cancer Institute, is the largest of its kind and the first to demonstrate how monitoring cancer cells circulating in the blood can be used to predict treatment success for this rare cancer-type, which most commonly affects the gut or pancreas.

Patients found to have circulating tumor cells (CTCs) in the blood at the start of treatment were around eight times more likely to die from their disease, compared to those with undetectable CTC levels.

Study leader Dr. Tim Meyer, who directs UCL ECMC, said: “By using state-of-the-art technology to count individual tumor cells circulating in the blood stream, we’ve been able to show how a simple test could help monitor treatment response and predict how fast the disease will progress. Doctors normally rely on CT or MRI scans to tell them if a treatment is working, but cutting-edge CTC testing can provide an overall snapshot of the tumour’s development, without the need to wait for changes in its size to become visible on scans.

“Although these findings are preliminary, CTC testing is already showing promise in advanced breast, prostate and colorectal cancers and, on the basis of these results, is being incorporated into several trials involving patients with neuroendocrine cancers. This will help uncover ways of determining the impact of treatment on a cellular level, helping tailor treatment to individual patients."

The researchers analysed from 118 patients with advanced neuroendocrine cancers attending the Royal Free Hospital. They compared the numbers of individual present in samples taken before and after treatment.

Patients whose CTC levels fell by more than two thirds within five weeks of starting a new treatment tended to have the best outcomes, while those whose CTC levels rose by more than a third did the worst.

Dr. Joanna Reynolds, Cancer Research UK’s director of centres, said: “This is a great example of how the Experimental Cancer Medicine’s Network is supporting cutting-edge research into rarer cancer types. Advanced cancers often consist of lots of smaller tumours around the body, many of which will be too tiny to be picked up by traditional imaging techniques, making it difficult to judge how well a drug is working. This study highlights a potential way to monitor response in real time across all cancer sites, so doctors know sooner if a isn’t working. Although at an early stage, this is an exciting area of research and we look forward to seeing how it progresses.”

More information: abstract.asco.org/AbstView_114_96900.html

add to favorites email to friend print save as pdf

Related Stories

Scientists reveal best imaging technique for ovarian cancer

Feb 15, 2012

Cancer Research UK-funded scientists have determined that a magnetic resonance imaging (MRI) technique, which measures the movement of water molecules within the tumour, may be the best way to monitor how women with late-stage ...

Recommended for you

How much overdetection is acceptable in cancer screening?

7 hours ago

People have highly variable views on how much overdetection is acceptable in cancer screening, finds a UK survey in The BMJ this week. The authors say invitations for screening "should include clear information on the li ...

Protein may be key to cancer's deadly resurgences

17 hours ago

Tumor recurrence following a period of remission is the main cause of death in cancer. The ability of cancer cells to remain dormant during and following therapy, only to be reactivated at a later time, frequently ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.